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ABSTRACT
Uncontrolled ﬁbrosis of skin and internal organs is the
main characteristic of scleroderma, and collagen is a
major extracellular matrix protein that deposits in the
ﬁbrotic organs. As the chaperone of collagen, heat
shock protein 47 (HSP47) is closely related with the
development of ﬁbrosis. To explore the potential func-
tion of HSP47 in the pathogenesis of scleroderma, the
clinical, in vivo and in vitro studies were performed. In
clinical, the increased mRNA level of HSP47 was
observed in the skin ﬁbroblasts and PBMC from scle-
roderma patients, and the enhanced protein level of
HSP47 was also detected in the skin biopsy and plasma
of the above patients. Unexpectedly, the enhanced
levels of HSP47 were positively correlated with the
presence of anti-centromere antibody in scleroderma
patients. Moreover, a high expression of HSP47 was
found in the skin lesion of BLM-induced scleroderma
mouse model. Further in vitro studies demonstrated that
HSP47 knockdown could block the intracellular and
extracellular collagen over-productions induced by
exogenous TGF-β. Therefore, the results in this study
provide direct evidence that HSP47 is involved in the
pathogenesis of scleroderma. The high expression of
HSP47 can be detected in the circulatory system of
scleroderma patients, indicating that HSP47 may
become a pathological marker to assess the progres-
sion of scleroderma, and also explain the systemic
ﬁbrosis of scleroderma. Meanwhile, collagen over-ex-
pression is blocked by HSP47 knockdown, suggesting
the possibility that HSP47 can be a potential therapeutic
target for scleroderma.
KEYWORDS systemic sclerosis, ﬁbrosis, collagen,
heat shock protein 47, anti-centromere antibody,
therapeutic target
INTRODUCTION
Systemic sclerosis (scleroderma, SSc) is a complex
autoimmune disease in which excessive accumulation of
extracellular matrix (ECM) in the skin and internal organs is a
major pathological ﬁnding. Although the etiology of this dis-
ease remains unknown, a number of therapeutic approaches
are available for treating scleroderma, including circulation
improvement, blocking production of certain pro-inﬂamma-
tory and pro-ﬁbrotic cytokines, as well as ﬁbrosis prevention
and treatment (Bournia et al., 2009; Sapadin and Fleis-
chmajer, 2002), due to vascular, immunologic and ﬁbrotic
alterations in SSc (Denton et al., 2006). However, none of
these treatments are consistently effective in attenuating
ﬁbrosis (Leask, 2012; Martin et al., 2012; Zandman-Goddard
et al., 2005). Therefore, a better assessment marker of the
ﬁbrosis activity and comprehensive understanding of the
underlying mechanisms of collagen over-production may
provide new strategies for the anti-ﬁbrotic treatment of SSc.Haiyan Chu and Ting Wu have contributed equally to this work.
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HSP47, a 47-kDa heat-shock protein, is initially charac-
terized as a cell surface-associated protein that binds type IV
collagen or gelatin, and later identiﬁed as a major collagen
binding heat-inducible protein in chick embryo ﬁbroblasts
(Kurkinen et al., 1984). HSP47 is a collagen-speciﬁc
molecular chaperone localized in the endoplasmic reticulum
(Saga et al., 1987), and belongs to the serpin family, a
superfamily of plasma serine protease inhibitors, but lacks
the active site essential for the inhibition of proteases (Hi-
rayoshi et al., 1991). During the maturation of collagen pro-
tein, HSP47 transiently binds to nascent pro-collagen once it
is co-translocated into the endoplasmic reticulum (ER) and
facilitates the assembly/secretion of collagens. After the tri-
ple helix collagen formation, HSP47 and the triple helix
proceed to the Golgi, where HSP47 dissociates from the pro-
collagen in the cis-Golgi complex (Nagata, 1998).
HSP47 has been reported to be involved in various
ﬁbrotic processes (Kakugawa et al., 2010; Masuda et al.,
1994), such as the experimental model of liver cirrhosis
(Masuda et al., 1994), pulmonary ﬁbrosis (Hagiwara et al.,
2007; Kakugawa et al., 2004; Kakugawa et al., 2010; Raz-
zaque et al., 1998), and peritoneal ﬁbrosis (Nishino et al.,
2003). As to the association of HSP47 with scleroderma,
HSP47 was found highly expressed in cultured ﬁbroblasts
from Japanese SSc together with type I collagen, which was
correlated with shorter disease duration (Kuroda et al.,
1998).
Since HSP47 is pivotal for the production of collagen,
which closely related to ﬁbrosis development of SSc, our aim
was to explore the role of HSP47 in the regulation of colla-
gen protein expression during ﬁbrosis development of SSc
and whether HSP47 would be a new serum marker to
assess the ﬁbrosis activity of the disease.
In this report, we provide evidences supporting that
HSP47 is indeed implicated in the systemic ﬁbrosis of SSc.
The expression of HSP47 is rather higher in the plasma,
peripheral blood mononuclear cells (PBMC) and skin biopsy
from SSc patients, as well as skin of bleomycin-induced
dermal ﬁbrosis model. In addition, the elevated expression of
HSP47 is positively correlated with presence of ACA in SSc
patients. And the blockade of HSP47 can inhibit the over-
production of collagen. Thus, the present data raising the
likelihood that HSP47 may be an indicator for ﬁbrosis activity
of SSc and presented as a potential therapeutic target for
SSc.
RESULTS
The expression of HSP47 was increased
in the peripheral blood mononuclear cells and plasma
from SSc patients
The peripheral blood mononuclear cells (PBMC) and plasma
from SSc patients were also collected to further clarify the
function of HSP47 in the development of SSc. The results
from ELISA assays showed that the secreted HSP47 was
elevated signiﬁcantly in the plasma of SSc patients compared
with that of normal controls (5.4 ± 0.2 ng/mL vs. 3.3 ± 0.1 ng/mL,
P = 0.0025; Fig. 1A). Furthermore, the HSP47 level in the
plasma from the patients with anti-centromere antibody was
signiﬁcantly higher than those without anti-centromere anti-
body (9.9 ± 1.6 ng/mL vs. 3.7 ± 0.07 ng/mL, P = 0.0315;
Fig. 1B). The HSP47 expression was also examined in the
PBMC of the above SSc patients, and it was found signiﬁ-
cantly increased by more than 2-fold (2.0 ± 0.1 vs. 0.8 ± 0.01,
P = 0.0312; Fig. 1C). Consistently, the mRNA level of HSP47
was signiﬁcantly up-regulated in the patients with anti-cen-
tromere antibody compared to those without anti-centromere
antibody by 1.5-fold (1.9 ± 0.14 vs.1.3 ± 0.04, P = 0.0393;
Fig. 1D). In addition, the transcription levels of COL1A2 and
COL3A1 in SSc patients were also markedly up-regulated
compared with those in normal controls about 8-fold and
7-fold, respectively (24.1 ± 2.0 vs. 3.1 ± 0.2 and 41.4 ± 3.8
vs. 6.0 ± 0.5, P = 0.0365 and P = 0.063, respectively; Fig. 1E
and 1F). Thus, it can be reasonably assumed that HSP47 is
implicated in the pathogenesis of scleroderma.
HSP47 was up-regulated in the skin lesion samples
and skin ﬁbroblasts obtained from SSc patients
Adjacent 4-µm-thick sections of ﬁbrotic skin from SSc
patients were collected for immunohistochemical staining for
HSP47 and α-smooth muscle actin (α-SMA). A greater
number of positive cells for both HSP47 and α-SMA with a
similar expression pattern were observed in SSc patients
compared with normal tissues (Fig. 2A and 2B). Meanwhile,
HSP47 positive cells were almost the same cells as α-SMA
positive staining, and most of those cells were myoﬁbrob-
lasts, indicating that HSP47 was mainly expressed in the
cells responsible for collagen synthesis (Fig. 2A). Therefore,
high expression of HSP47 was associated with the exces-
sive collagen production in SSc patients.
Fibroblasts were cultured from the skin tissues of Chinese
Han SSc patients to measure HSP47 expression. As illus-
trated in Fig. 2, the protein levels of HSP47 and COL1 were
signiﬁcantly upregulated in the SSc dermal ﬁbroblasts
compared with those from normal controls by about 3.5-folds
and 1.5-folds, respectively (Fig. 2C). The transcription level
of HSP47 was increased by 8-fold and (Fig. 2D). And the
expression of TGF-β was also found up-regulated in the
cultured skin ﬁbroblast of SSc patients as examined previ-
ously (Wu et al., 2014).
Expression of HSP47 was increased in the scleroderma
mouse model
To further demonstrate the role of HSP47 in the pathogen-
esis of SSc, the scleroderma mouse model was stablished in
our study. As demonstrated by our previous study, the his-
tological and molecular hallmarks that are similar to SSc
patients are present in the bleomycin-treated mice
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established in our study (Wang et al., 2010; Wang et al.,
2011). As shown in Fig. 1, compared with saline treated
mice, BLM induced marked hypodermal thickness (Fig. 3A
and 3B), increase of ECM deposition and collagen contents
(Fig. 3C and 3D), enhancement of the transcription levels of
Col1a2 and Col3a1. Furthermore, HSP47 expression level
was examined in this mouse model. There was a signiﬁcant
(5-fold) increase in transcription level of Hsp47 (Fig. 3E), and
a signiﬁcant (2-fold) increase in the protein level of HSP47
(Fig. 3F). Therefore, HSP47 was highly expressed in the skin
tissues from BLM-induced SSc mouse model. Meanwhile,
mRNA level of Tgf-β was increased in the skin lesion of the
SSc mice model (Fig. 3G).
Inhibition of HSP47 expression may block exogenous
TGF-β-induced increases in collagen
To further explore the potential role of HSP47 in collagen
production during the ﬁbrogenesis of SSc, HSP47 expres-
sion was inhibited by corresponding siRNA transfection, and
then the intracellular and extracellular collagens were
examined by Western blot and Sircol assay, respectively. As
shown in Fig. 4A, TGF-β stimulation could increase the
protein levels of HSP47 and type I collagen, whereas the
collagen expression was decreased by knockdown of Hsp47
(Fig. 4A). In addition, collagen secretion was also reduced
after knockdown of Hsp47 (Fig. 4B). Therefore, these results
strongly suggested that HSP47 could play an essential role
in promoting collagen synthesis and secretion during the
ﬁbrogenesis of SSc.
The expression of HSP47 was prominently increased
by exogenous TGF-β induction in a dose-dependent
manner
TGF-β is a well-known potential pro-ﬁbrogenic cytokine. The
NIH/3T3 ﬁbroblasts stimulated by exogenous TGF-β could
display SSc-like phenotype (Wu et al., 2014). Given these
two reasons, NIH/3T3 ﬁbroblasts were used to test the
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Figure 1. The protein level of HSP47 in the plasma and the mRNA level of HSP47 in the peripheral blood mononuclear cells
were both elevated in the SSc. (A) As assessed by ELISA, the level of HSP47 was elevated in the plasma of SSc patients
compared with that of normal people (5.4 ± 0.2 ng/mL vs. 3.3 ± 0.1 ng/mL). (B) The level of HSP47 was elevated in the plasma of
patients with anti-centromere antibody compared to patients without anti-centromere antibody (9.9 ± 1.6 ng/mL vs 3.7 ± 0.07 ng/mL).
(C) Relative mRNA levels of HSP47 in the PBMC for SSc (2.0 ± 0.1) vs. normal control (0.8 ± 0.01) using RT-PCR. (D) The relative
levels of mRNA of HSP47 in PBMC of patients with anti-centromere antibody compared to patients without anti-centromere antibody
(1.9 ± 0.14 vs. 1.3 ± 0.04). (E) The relative mRNA levels of COL1A2 in the PBMC were SSc (24.1 ± 2.0) vs. normal (3.1 ± 0.2). (F) The
relative mRNA level of COL3A1 in the PBMC were SSc (41.4 ± 3.8) vs. normal (6.0 ± 0.5). The mRNA levels of those genes were
calculated using a relative ratio to GAPDH. The y axis is plotted on a logarithmic scale. Values show the means ± SEM. *P < 0.05,
**P < 0.01.
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of HSP47 expression. The results suggested that both
HSP47 expression and collagen production were increased
by TGF-β induction in a dose-dependent manner, and the
maximum level of both the HSP47 expression and collagen
production were observed at 10 ng/mL of TGF-β. In addition,
the mRNA level of Hsp47 was enhanced by TGF-β at 12 h
and the protein level was elevated at 48 h, respectively
(Fig. 5A–D). The results conﬁrmed that the expression of
HSP47 could be regulated by TGF-β.
DISCUSSION
SSc is a complex immune connective tissue disorder with
the main characteristic of ﬁbrosis in skin and multiple visceral
organs. Despite the fact that numerous hypotheses involving
ﬁbrosis development have been investigated, the underlying
mechanism has not yet been discovered (Bhattacharyya
et al., 2012; Broen et al., 2012; Hunzelmann and Brinck-
mann, 2010; Martin et al., 2012; Rabquer and Koch, 2012).
The uncontrolled synthesis and excessive deposition of
collagen are the main characteristics of ﬁbrotic disorders.
Thus, a thorough understanding of the mechanism regulat-
ing collagen synthesis is essential to develop better thera-
pies to ameliorate ﬁbrosis. HSP47 is a collagen-speciﬁc
molecular chaperone that is essential for the biosynthesis of
collagen molecule (Nagata, 1998), and both in vivo and
in vitro studies have highlighted the importance of HSP47 in
the pathogenesis of various ﬁbrotic diseases. The present
work was designed to determine the role of HSP47 in
ﬁbrogenesis of SSc.
In a previous study reported by Fujimoto M and his col-
leagues that the HSP47 antibody was elevated in the serum
of SSc patients (Fujimoto et al., 2004), however, the expres-
sion level of HSP47 protein in the serum was unclear, and our
study found that an elevated HSP47 protein level was
observed in the plasma of SSc patients, at the same time, the
mRNA level of HSP47 was also found elevated in the PBMC
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Figure 2. Expression of HSP47 in normal people and SSc patients’ skin. (A) IHC for HSP47 and α-SMA in skin biopsy from ﬁve
SSc patients and HSP47 positive cells were localized on the α-SMA positive cells. (B) IHC for HSP47 and α-SMA in skin biopsy from
three normal human. Compared with normal controls, signiﬁcant increase of HSP47 and α-SMA expression in the skin of SSc
patients was observed. Arrows indicate the positive cells, and arrows with the same color indicate the same cells. The length of bars
in the ﬁgures with an original magniﬁcation of 100× are 100 μm, and the length of bars in the ﬁgures with an original magniﬁcations of
400× are 20 μm. (C) Western blot analysis revealed increased expression of HSP47 and COL1 in the ﬁbroblasts from the skin of SSc
patients, and densitometric analysis results of Western blot for HSP47 and COL I were shown in the column chart. (D) RT-PCR
revealed signiﬁcant increases in the mRNA levels of HSP47 in the ﬁbroblasts cultured from SSc patients’ skin compared with those
from normal controls. *P < 0.05, **P < 0.01 vs. normal control. Experiments were repeated three times.
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Figure 3. Expression of HSP47 increased in the skin lesions of mice treated with BLM. (A) Hematoxylin and eosin (H&E) and
Trichromestaining for the skin tissues of normal control mice and BLM-treated mice, Original magniﬁcations were 200×, and the
length of bars in the ﬁgures are 100 μm; (B) Dermal thickness was calculated at 10× microscopic magniﬁcation by measuring the
distance between the dermal-epidermal junction and the derma-subcutaneous fat junction (μm) (as indicated by H&E staining of in
Fig. 1A) in ﬁve randomly selected ﬁelds for each skin section. (C) Deposition of collagen in the skin was examined by Sircol assay.
RT-PCR was used to analyze the expression of collagen (D), Hsp47 (E) and Tgf-β (G) in the skin of mice, and the mRNA levels were
calculated using a relative ratio to Gapdh. (F) Western blots for the protein level of HSP47 in mice skin, and densitometric data of
Western blot for HSP47 was shown in the column chart. Bars show the means ± SEM results from 6 mice in each group. *P < 0.05,
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Figure 4. The effect of HSP47 on the production of collagen. (A) NIH/3T3 cell was incubated with exogenous TGF-β for 24 h, then
transiently transfected with Hsp47 siRNA for another 24 h, scramble siRNA as control, HSP47 and type I collagen protein were
determined by Western blot and the densitometry data of Western blot for HSP47 and type I collagen proteins were shown in the
column chart. (B) The collagen content in the cell supernatant was measured by Sircol assay. Values are expressed as means ±
SEM. *P < 0.05, **P < 0.01 vs. normal control. Experiments were repeated three times.
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of the ﬁbrosis activity of SSc. Since HSP47 has intracellular
location and does not secrete out of cells, it seems that the
elevated sera level of HSP47 in mixed connective tissue
disease (MCTD) and rheumatic diseases (Yokota et al., 2003)
and the higher plasma level of HSP47 detected in SSc in our
study are produced by the apoptotic cells under the inﬂam-
matory and ﬁbrotic condition. Whereas our further analysis
demonstrated that both mRNA and plasma levels of HSP47
had a signiﬁcant correlation with the presence of anti-cen-
tromere antibody, which is usually more common in patients
with limited scleroderma, and a biomarker for better prognosis
for SSc patients (Mehra et al., 2013). Thus, an increased level
of HSP47 might be a potential serum biomarker for better
prognosis of SSc patients.
Further analysis found the transcription levels of both
HSP47 and collagen genes were signiﬁcantly elevated in the
PBMCs of SSc patients. To the best of our knowledge, this is
the ﬁrst report that the expressions of HSP47 and collagen
genes are up-regulated in the PBMC of SSc patients, which
may provide an explanation for the systemic ﬁbrosis of SSc
due to the circulating of PBMC in the body. Previous studies
have described a newly characterized collagen-secreting
cell type named circulating ﬁbrocyte in the PBMC, which was
associated with various ﬁbrotic disorders, such as sclero-
derma and pulmonary diseases (Quan et al., 2004; Quan
et al., 2006). Thus, we hypothesized that the circulating
ﬁbrocytes from PBMCs might produce the collagen and
HSP47 in SSc patients and contributed to ﬁbrogenesis of
SSc.
Myoﬁbroblasts, characterized by expressing α-SMA
(Jercan et al., 2012) is the major cell type responsible for
secretion of the ECM proteins (e.g., collagen isoforms, cel-
lular ﬁbronectin, etc.) (Kach et al., 2013), and a signiﬁcant
increase in myoﬁbroblasts has been previously observed in
the skin of scleroderma patients (Krieg et al., 2007). HSP47
was found mainly expressed in the α-SMA-positive cells
(Fig. 2), i.e. myoﬁbroblasts (Abraham et al., 2009) and the
number of HSP47-positive cells determined by IHC in the
present study was also increased in the skin tissues from
SSc patients, suggesting a potential role of HSP47 in the
development of SSc ﬁbrosis. Up-regulation of HSP47 was
further conﬁrmed in the dermal ﬁbroblasts from SSc patients,
and was in accordance with the high expression levels of
type I and type III procollagens in the present study (Fig. 2).
The up-regulation of HSP47 was also observed in the BLM-
induced SSc mouse model, and was correlated with the
increased production of collagen, further conﬁrming its role
in the excessive production and deposition of collagen in
SSc.
TGF-β increases the production of ECM and induces
ﬁbrosis (Xiao et al., 2012; Yan et al., 2009) and its expres-
sion is highly related to the pathogenesis of scleroderma.
TGF-β can also induce HSP47 expression by enhancing the
heat shock element binding activity of heat shock tran-
scription factor (Sasaki et al., 2002). Our results showed that
HSP47 was up-regulated by TGF-β in a dose-dependent
manner; meanwhile, collagen genes were also up-regulated
in the same manner (Fig. 5), suggesting that TGF-β signaling
might be involved in the modulation of HSP47 expression
during SSc ﬁbrosis development. Although TGF-β plays a
fundamental role in the progression of ﬁbrosis, it is also a




















































































































Figure 5. TGF- β increases expression of HSP47 and collagen in a dose-dependent manner. (A) Treatment with TGF-β for 48 h
increased the protein level of HSP47 and type I collagen in a dose-dependent manner and densitometric analysis of Western blot for
HSP47, COLI were shown in the column chart. RT-PCR revealed increased Hsp47 (B), type I collagen (C), and type III collagen
(D) mRNA after treatment with TGF-β for 12 h. Relative mRNA was calculated using a relative ratio to Gapdh. Values are expressed
as means ± SEM. *P < 0.05, **P < 0.01 vs. normal control. Experiments were repeated three times.
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physiological processes, and not suitable as a target for
ﬁbrosis therapy. Little progress has been made in developing
TGF-β pathway inhibitors as anti-ﬁbrotic drugs. Therefore,
therapeutic strategies for SSc and some other ﬁbrotic dis-
orders may be designed by blockade of HSP47 expression,
the downstream effector of TGF-β signaling, to ameliorate
ﬁbrosis. As a collagen-speciﬁc chaperone, HSP47 is impli-
cated in the posttranslational stage of collagen, which is the
mature and/or secretion of pro-collagen molecules. We
found that the expression of HSP47 did have an effect on the
transcription level of collagens. It was plausible that block-
ade of HSP47 expression could result in the accumulation of
insoluble aggregates within the ER of the cells (Ishida et al.,
2006), which provided a negative feedback of transcriptional
regulation of collagens. Thus, HSP47 inhibition with siRNA
or some other inhibitors might be a good choice for the
treatment of ﬁbrotic disorders without disrupting the cellular
homeostasis and with fewer side effects.
In the same time, we have noticed that knockdown of
Hsp47 signiﬁcantly prevented induction of the lower band
detected by anti-ColI antibody, but slightly prevented that of
the upper band, which may due to the following reasons. The
upper band is α1(I) and the lower band is α2(I). It was
reported that TGF-β interacts with Smad binding element
(SBE) in the promoter origin of the collagen genes (Derk and
Jimenez, 2003; Leask and Abraham, 2004; Verrecchia et al.,
2006), making no difference in the expressions of α2(I) and
α1(I) genes by exogenous TGF-β stimulation. However,
treatment with antisense oligonucleotide against Hsp47
efﬁciently blocked the production of procollagen α2(I) protein
other than α1(I) protein (Ohba et al., 2003). Thus, the
knockdown of Hsp47 might only affect the expression of
α2(I), which is the lower band in the WB ﬁgure.
In summary, the results provided herein present clear
evidence that HSP47 is involved in ﬁbrogenic process of
scleroderma and collagen expression is regulated, at least
partially, by HSP47. The expression of HSP47 is conﬁrmed
to be regulated by the proﬁbrogenic cytokine TGF-β, and
further investigations should be performed to validate this
potential prognosis biomarker for SSc patients and important
therapeutic target for ﬁbrosis disorders.
MATERIALS AND METHODS
Patients
Fifty-four Chinese patients who were fulﬁlled the criteria for diag-
nosis with SSc were enrolled from Shanghai Traditional Chinese
Medicine-Integrated Hospital (Table 1) Masi (1980). Laboratory
tests were conducted for all patients to conﬁrm the diagnosis for
SSc. Thirty-eight age- and gender-matched healthy individuals
were enrolled as normal controls. All the participants provided
written informed consent for the sample collection and subsequent
analysis. The present study was approved by and carried out in
accordance with the guidelines of the School of Life Sciences,
Fudan University.
Establishment of skin ﬁbrosis mouse model
Speciﬁc pathogen-free, female C3H mice (7 weeks old; Sino-British
Sippr/BK Lab Animal Ltd., Shanghai, China) were provided ad libitum
water and pelleted food at the Animal Centre of State Key Laboratory
of Genetic Engineering, School of Life Sciences, Fudan University.
Bleomycin (BLM; Nippon Kayaku, Tokyo, Japan) was dissolved in
saline at 200 μg/mL. Filter-sterilized BLM or saline was injected (100
μL) subcutaneously into the same site of the shaved upper back daily
for 3 weeks. All the animal protocols were approved by the School of
Life Sciences, Fudan University, China (Wu et al., 2014).
Primary human skin ﬁbroblasts culture
Skin biopsy specimens were obtained from ﬁve SSc patients (four
females and one male; three diffuse cutaneous SSc (dcSSc) and
two limited cutaneous (lcSSc), the average age was 21.6 ± 6.6 years
(mean ± SD), who were fulﬁlled the criteria for SSc as deﬁned by the
American College of Rheumatology (formerly the American
Rheumatism Association) (1980). Skin biopsy specimens from nor-
mal controls with no history of autoimmune and other dermal dis-
eases were used as control comparators. Skin samples were
transported in Dulbecco’s modiﬁed Eagle’s medium (DMEM) sup-
plemented with 10% fetal calf serum (FCS) for processing the same
day. The skin samples were washed in 75% ethanol, phosphate
buffered saline (PBS), and DMEM with 10% FCS. Cultured ﬁbroblast
strains were established by mincing tissues and placing them into
60-mm culture dishes secured by glass overlays. The third to ﬁfth
passage of human dermal ﬁbroblasts were placed into 12-well cul-
ture plates at the density of 1 × 105 cells per well for gene and
protein expression assays.
Cell culture and exposure to TGF-β
Mouse embryonic NIH/3T3 ﬁbroblasts were cultured in DMEM
medium supplemented with 10% FCS at 37°C in a 5% CO2
humidiﬁed incubator. After 12 h of serum starvation in serum-free
media, ﬁbroblasts were exposed to recombinant human TGF-β
Table 1. Clinical and laboratory data of patients with SSc









Anti-centromere antibody 10 (20.0%)
Anti-U1RNP antibody 10 (19.6%)
Anti-RNA polymerase antibody 1 (2.0%)
Lung involvement 38 (80.8%)
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(R&D Systems, Inc., Minneapolis, MN, USA) at gradient concen-
trations of 0, 1.25, 2.5, 5.0, and 10.0 ng/mL for 12, 24, 36, and 48 h
for RNA and protein collection.
Preparation and transfection of Hsp47 siRNA
Mouse Hsp47 siRNA and non-silencing siRNA were purchased from
Dharmacon (USA). For siRNA transfection, NIH/3T3 ﬁbroblasts in a
12-well culture plate were cultured with or without TGF-β for 24 h,
and then transfected with Hsp47 siRNA or non-silencing siRNA
using Lipofectamine RNAiMAX (Invitrogen) at a concentration of
50 nmol/L. The cells were harvested 48 h after transfection for gene
and protein expression assays.
Histologic analysis
For the assessment of histopathological changes, skin tissues were
ﬁxed with 4% paraformaldehyde and embedded in parafﬁn. Then
4-μm-thick skin sections were stained with hematoxylin/eosin or
Masson’s trichrome staining for better visualization of the tissue
structure. Dermal thickness was analyzed with a Nikon Eclipse 80i
microscope (Nikon, Badhoevedorp, The Netherlands) by measuring
the maximal distance between the epidermal-dermal junction and
the dermal-subcutaneous fat junction at 4 different skin sections in
each mouse, as previously described (Yoshizaki et al., 2010). The
evaluation was performed by two independent examiners.
RT-PCR and quantitative RT-PCR analysis
Total RNA was extracted from the skin of mice, human skin ﬁbroblasts
(described in the Primary human skin ﬁbroblasts culture section
above), and peripheral blood mononuclear cell isolated from patients
and normal individuals’ blood (described in the Patients section
above) using Trizol (Invitrogen, Carlsbad, CA, USA). One microgram
of total RNA was subjected to cDNA synthesis using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems)
according to the instructions of the manufacturer. The speciﬁc primers
for each gene were designed using Primer 5 and synthesized by
Generay Biotech Co., Ltd. (Shanghai, China). The RT-PCR ampliﬁ-
cation was conducted using a SYBR Green I PCR Kit (TaKaRa,
Shiga, Japan) according to manufacturer’s instructions. The reaction
was carried on ABI Prism 7900 Detector System (Applied Biosys-
tems). RT-PCR conditions were 95°C for 3 min, followed by 40 cycles
of 95°C for 15 s, 60°C for 40 s, and the conditions for getting the
dissociation curve was 95°C for 15 s, 60°C for 15 s, 95°C for 15 s. The
data obtained from the assays were analyzed with SDS 2.3 software
(Applied Biosystems). For each sample, the relative gene expression
was calculated using a relative ratio to Gapdh/GAPDH.
Collagen measurements
Total soluble collagen from mice skins and cell culture supernatants
was quantiﬁed using the Sircol collagen assay (Biocolor, Belfast,
UK). In detail, collagen of the mice skins was extracted overnight
with 2 mg/mL pepsin in 5 mol/L acetic acid, while collagen secreted
from cultured cells were collected from the supernatant of conﬂuent
cells which were incubated for 24 h with 1 mL DMEM and 5% FCS in
25-cm2 culture dishes. Then, 1 mL of Sirius red dye, an anionic dye
that reacted speciﬁcally with basic side chain groups of collagens
under assay conditions, was added to 20 μL collagen solution of
mouse skin or 400 μL of cell supernatant, and incubated with gentle
rotation for 30 min at room temperature. After centrifugation at
12,000 ×g for 10 min, the collagen-bound dye was re-dissolved with
1 mL of 0.5 mol/L NaOH, and the absorbance at 555 nm was
measured. The absorbance is directly proportional to the amount of
collagen in skin tissues and cell supernatants.
ELISA for HSP47 in plasma
The concentrations of HSP47 in the plasma of SSc patients were
measured using an ELISA kit (Abcam, Hong Kong, Ltd.) according
to the manufacturer’s instructions.
Western blot analysis
The cell lysates extracted from the skin tissues of mice and the
cultured cells were used for immunoblotting analysis. Total protein
concentration was measured using the BCA protein kit (Vazyme,
China) with bovine serum albumin (BSA, Sigma-Aldrich) as the
standard protein. Equal amounts of protein from each sample were
subjected to 10% SDS PAGE gels electrophoresis, and subse-
quently transferred to PVDF membranes (Millipore). The mem-
branes were blocked with 5% milk at room temperature for 1 h. Then
the membranes were incubated with rabbit anti-HSP47 monoclonal
antibody (1:1000) (Abcam, Hong Kong, Ltd.), rabbit anti-alpha-SMA
monoclonal antibody (1:50000) (Millipore, clone E184), goat anti-
Collagen type I polyclonal antibody (1:500) (Millipore), rabbit anti-
mouse anti-Collagen type I polyclonal antibody (1:500; Millipore) or
internal control GAPDH antibody (Cell Signaling Technology) at 4°C
overnight. After three washes with TBST for 30 min, the PVDF
membranes were incubated with the horseradish peroxidase-con-
jugated secondary antibody of goat anti-rabbit, rabbit anti-goat or
goat anti-mouse lgG for 1 h at room temperature. The protein bands
were visualized using an enhanced chemiluminescence system
(Thermo) and the intensity of bands was quantiﬁed using Image-
QuantTL software (General Electric Company).
Immunohistochemical staining of α-SMA and HSP47
For immunohistochemistry assay, the primary antibodies used were
anti-α-SMA (1:500; Millipore, clone E184) and monoclonal anti-
HSP47 antibodies (1:200; Abcam, Hong Kong, Ltd.). Skin tissues
obtained from ﬁve patients (ﬁve females; median age 27 years,
range 13–43 years) and normal controls were formalin-ﬁxed and
parafﬁn-embedded. Skin sections were deparafﬁnized and incu-
bated with 5% bovine serum albumin for 60 min. Cells positive for α-
SMA and HSP47 were detected by incubation with the primary
antibody for 2 h at room temperature followed by incubation with 3%
hydrogen peroxide for 10 min. Goat anti-rabbit lgG labeled with
horseradish peroxidase were used as secondary antibodies. The
expression of α-SMA and HSP47 was visualized with 3,3’-di-
aminobenzidinetetrahydrochloride (DAB-4HCl).
Statistical analysis
An independent two group t-test or one-way Analysis of Variance
(ANOVA) with LSD multiple comparison tests were used to evaluate
RESEARCH ARTICLE Haiyan Chu et al.









signiﬁcant differences between groups. P values less than 0.05 were
considered signiﬁcant.
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